Leap Therapeutics Inc LPTX

NAS: LPTX | ISIN: US52187K1016 30/04/2025

0,418 USD (+7,95%)

(+7,95%) 30/04/2025

Grafiek Leap Therapeutics Inc

Grafiek Leap Therapeutics Inc

1 dag1d 7,95%
1 week1w 6,36%
1 maand1m 43,53%
3 maanden3m -20,12%
6 maanden6m -88,82%
1 jaar1j -87,21%
5 jaar5j -80,46%

Leap Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

25 april 2025 · Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting · Persbericht

15 april 2025 · Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer · Persbericht

26 maart 2025 · Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results · Persbericht

26 maart 2025 · Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study · Persbericht

12 augustus 2024 · Leap Therapeutics Reports Second Quarter 2024 Financial Results · Persbericht

13 mei 2024 · Leap Therapeutics Reports First Quarter 2024 Financial Results · Persbericht

11 april 2024 · Leap Therapeutics Announces $40 Million Private Placement · Persbericht

18 maart 2024 · Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results · Persbericht

16 januari 2024 · Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium · Persbericht

3 januari 2024 · Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

Profiel Leap Therapeutics Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.leaptx.com

Hoofdzetel: Cambridge, Massachusetts Verenigde Staten

Werknemers: 34

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe